RE:RE:Keytruda resistance shown as a monotherapy in anal cancerTwo different studies in metastatic or locally advanced incurable anal squamous cell carcinoma. One with pembrolizumab as a monotherapy and one with pelareorep in combination with atezolizumab.
The monotherapy pembrolizumab study reported an ORR of 9.4% and a 2.2 month PFS.
The I/O combination pelareorep + atezolizumab study reported an ORR of 35.5% and results that have exceeded historical control trials.
Just on these results one can conclude that pelareorep, when added to an immune checkpoint inhibitor, results in a 4 fold improvement in ORR, which demonstratres synergy with an immune checkpoint inhibitor and is considered a biomarker for future response rate.